NAGE
Niagen Bioscience, Inc.
3.00$
+0.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +70.1% | +11.0% | |
| – | – | +4.8% | -1.8% | +3.0% | -13.8% | -21.6% | -4.2% | +28.0% | +26.9% | +70.7% | +17.6% | +80.9% | -0.7% | +7.5% | +15.9% | -9.5% | -13.0% | -2.3% | |
| – | – | +69.9% | +513.1% | +135.3% | -9.0% | -52.4% | +126.5% | -32.2% | -39.6% | +285.7% | +38.3% | +12.6% | -3.3% | -10.7% | -7.4% | -17.2% | -23.0% | +65.9% | |
| – | – | – | – | – | -611.3% | – | – | – | – | – | +158.9% | -91.8% | +152.9% | -538.1% | – | – | -32.2% | -364.7% | |
| – | – | -62.8% | +7.9% | -11.3% | -56.7% | +195.6% | +11.2% | +157.3% | +166.3% | -21.7% | +7.5% | -48.1% | -81.1% | +188.0% | -18.3% | -55.7% | +10.1% | +79.1% | |
| – | – | -63.8% | +10.9% | -11.3% | -56.7% | – | +59.2% | -140.7% | +166.3% | – | -138.6% | -86.0% | -33.7% | +147.9% | -18.3% | -57.2% | +0.0% | +104.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -48.4% | -6.3% | -26.7% | +9.1% | |
| – | +370,059.7% | -102.4% | – | -46.5% | +317.0% | -54.9% | -42.1% | +61.3% | -82.6% | +6,389.5% | -100.2% | – | -48.8% | +317.3% | -78.8% | -101.2% | – | +30.1% | |
| – | – | -179.6% | – | -202.9% | – | +1,644.0% | -2.2% | -7.0% | -346.5% | – | -152.1% | – | – | – | -167.5% | – | +151.8% | +16.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +71.4% | +10.0% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.